Five-year survival model
| . | Survived∗ >5 y . | Died ≤5 y . | Univariable (P value)† . | Multivariable (P value)† . |
|---|---|---|---|---|
| Discovery cohort (n = 38)‡ | ||||
| Age (y) | 53.6 ± 15.2 | 62.1 ± 10.9 | .150 | .422 |
| Time from diagnosis (y)§ | 3.4 ± 4.6 | 5.1 ± 5.2 | .380 | .990 |
| Sex (female/male)|| | 17/10 | 3/8 | .110 | .949 |
| Advanced SM (yes/no)|| | 5/22 | 6/5 | .029 | .078 |
| TNF (high/low)|| | 4/23 | 9/2 | <.001 | .008 |
| AP (high/low)|| | 5/22 | 6/5 | .009 | .186 |
| Serum tryptase (high/low)|| | 3/4 | 6/5 | .010 | .359 |
| S/A/R mutation (yes/no)||,¶ | 1/26 | 1/10 | .690 | .227 |
| Validation cohort (n = 132)# | ||||
| Age (y) | 49.0 ± 14.3 | 65.2 ± 11.6 | <.001 | .097 |
| Time from diagnosis (y)¶ | 3.2 ± 4.1 | 2.4 ± 5.1 | .37 | .017 |
| Sex (female/male)|| | 64/44 | 6/18 | .003 | .329 |
| Advanced SM (yes/no)|| | 14/94 | 20/4 | <.001 | <.001 |
| TNF (high/low)|| | 9/99 | 19/5 | <.001 | .028 |
| AP (high/low)|| | 25/83 | 16/8 | <.001 | .108 |
| Serum tryptase (high/low)|| | 12/96 | 11/13 | <.001 | .832 |
| S/A/R mutation (yes/no)||,¶ | 2/106 | 16/8 | <.001 | .047 |
| . | Survived∗ >5 y . | Died ≤5 y . | Univariable (P value)† . | Multivariable (P value)† . |
|---|---|---|---|---|
| Discovery cohort (n = 38)‡ | ||||
| Age (y) | 53.6 ± 15.2 | 62.1 ± 10.9 | .150 | .422 |
| Time from diagnosis (y)§ | 3.4 ± 4.6 | 5.1 ± 5.2 | .380 | .990 |
| Sex (female/male)|| | 17/10 | 3/8 | .110 | .949 |
| Advanced SM (yes/no)|| | 5/22 | 6/5 | .029 | .078 |
| TNF (high/low)|| | 4/23 | 9/2 | <.001 | .008 |
| AP (high/low)|| | 5/22 | 6/5 | .009 | .186 |
| Serum tryptase (high/low)|| | 3/4 | 6/5 | .010 | .359 |
| S/A/R mutation (yes/no)||,¶ | 1/26 | 1/10 | .690 | .227 |
| Validation cohort (n = 132)# | ||||
| Age (y) | 49.0 ± 14.3 | 65.2 ± 11.6 | <.001 | .097 |
| Time from diagnosis (y)¶ | 3.2 ± 4.1 | 2.4 ± 5.1 | .37 | .017 |
| Sex (female/male)|| | 64/44 | 6/18 | .003 | .329 |
| Advanced SM (yes/no)|| | 14/94 | 20/4 | <.001 | <.001 |
| TNF (high/low)|| | 9/99 | 19/5 | <.001 | .028 |
| AP (high/low)|| | 25/83 | 16/8 | <.001 | .108 |
| Serum tryptase (high/low)|| | 12/96 | 11/13 | <.001 | .832 |
| S/A/R mutation (yes/no)||,¶ | 2/106 | 16/8 | <.001 | .047 |
AP, alkaline phosphatase.
Or censored.
Univariable or multivariable Cox regression.
Exclusion of 2 patients with incomplete data.
Time between diagnosis and sample collection.
Binary variables (cutoff values: TNF 2.96 pg/mL in the discovery cohort and 1.235 pg/mL in the validation cohort based on different generations of the TNF ELISA applied; alkaline phosphatase 100 U/L; and serum tryptase 125 ng/mL).
SRSF2, ASXL1, and RUNX1 mutation status.
Exclusion of 1 statistical outlier and 9 patients with incomplete data.